Michael A. Gorin
Expertise in
26
conditions

Dr. Michael A. Gorin

Urology
12234 Williams Rd, 
Cumberland, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
26
conditions
12234 Williams Rd, 
Cumberland, MD 

Overview

Michael A. Gorin is a Urologist in Cumberland, Maryland. He has been an author of 279 peer-reviewed articles and participated in 4 clinical trials in the past 15 years. Dr. Gorin is a member of the Focal Therapy Society, Endourology Society, and an associate member of the American Urological Association. He is licensed to treat patients in Maryland and New York.

Dr. Gorin is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Renal Oncocytoma, Prostate Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Prostatectomy.

Dr. Gorin is board certified in American Board Of Urology. He is actively involved in clinical research, co-authoring 356 peer reviewed articles and participating in 9 clinical trials.

Residency

Johns Hopkins University School of Medicine

Specialties

Urology

Licenses

Urology in MD

Board Certifications

American Board Of Urology

Hospital Affiliations

Mount Sinai South Nassau

Languages Spoken

English

Gender

Male

Awards

Star Reviewer for Urologic Oncology: Seminars and Original Investigation
William F. Rienhoff, Jr., M.D. Scholar Award, Johns Hopkins University School of Medicine
Best Reviewer Award, 32nd Annual Meeting of the Engineering & Urology Society
Resident Research Award, Annual Residency Retreat, The James Buchanan Brady Urological Institute

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Nippon Life
  • INSURANCE PLAN
Northwell Health
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

UPMC Western Maryland
12234 Williams Rd, Cumberland, MD 21502

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin
Study Phase: Phase 3
A Phase II Study to Evaluate the Performance of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer in Men With an Elevated PSA
A Phase II Study to Evaluate the Performance of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer in Men With an Elevated PSA
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drug: 18F-DCFPyL Injection
Study Phase: Phase 2
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
Enrollment Status: Completed
Publish Date: December 19, 2025
Intervention Type: Drug, Radiation
Study Drug: Radium-223
Study Phase: Phase 2
Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Other, Drug
Study Drug: Flutamide
Study Phase: Early Phase 1
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
Enrollment Status: Completed
Publish Date: August 09, 2021
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 3
Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 29, 2020
Intervention Type: Drug, Procedure
Study Phase: Not Applicable
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma
Enrollment Status: Completed
Publish Date: July 30, 2019
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
Enrollment Status: Completed
Publish Date: April 10, 2019
Intervention Type: Drug, Diagnostic test
Study Phase: Phase 3
View 8 Less Clinical Trials

356 Total Publications

Quantitative Reconstructions for Renal Sestamibi SPECT/CT: A Modeled Comparison of 360-Degree Versus 180-Degree Acquisitions.
Quantitative Reconstructions for Renal Sestamibi SPECT/CT: A Modeled Comparison of 360-Degree Versus 180-Degree Acquisitions.
Journal: Nuklearmedizin. Nuclear medicine
Published: August 11, 2026
Similar Doctors
Expertise in
44
conditions
Expertise in
44
conditions
Referral may be required

UPMC Western Maryland

12500 Willowbrook Rd, 
Cumberland, MD 
 (0.5 miles away)
240-964-7000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jason Riley is a Urologist practicing medicine in Cumberland, Maryland. He has been practicing medicine for over 17 years. Dr. Riley is highly rated in 44 conditions, according to our data. His clinical expertise encompasses UPJ Obstruction, Perirenal Abscess, Boils, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Riley is currently accepting new patients.

Expertise in
44
conditions
Expertise in
44
conditions
Referral may be required

UPMC Western Maryland Health Services LLC

23789 Garrett Hwy, 
Mc Henry, MD 
 (33.4 miles away)
301-724-0132
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Allaway is a Urologist practicing medicine in Mc Henry, Maryland. Dr. Allaway is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Interstitial Cystitis, Ureteroscopy, and Prostatectomy. Dr. Allaway is currently accepting new patients.

Expertise in
49
conditions
Expertise in
49
conditions
Referral may be required

UPMC Western Maryland Health Services LLC

23789 Garrett Hwy, 
Mc Henry, MD 
 (33.4 miles away)
301-724-0132
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

Vasil Parousis is a Urologist practicing medicine in Mc Henry, Maryland. Dr. Parousis is highly rated in 49 conditions, according to our data. His clinical expertise encompasses Male Pseudohermaphroditism with Gynecomastia, Eunuchoidism Familial Hypogonadotropic, Kidney Stones, Testicular Failure, and Ureteroscopy. Dr. Parousis is currently accepting new patients.

Frequently Asked Questions about Dr. Michael A. Gorin

How do I make an appointment with Dr. Michael A. Gorin?

You can book an appointment with Dr. Michael A. Gorin by calling their office at 301-724-0132. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael A. Gorin a top-rated expert for Renal Oncocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael A. Gorin is classified as an Elite expert for Renal Oncocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael A. Gorin specialize in?

While Dr. Michael A. Gorin is a Urology, they have specific expertise in Renal Oncocytoma, Prostate Cancer, and Renal Cell Carcinoma (RCC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Urology.

Does Dr. Michael A. Gorin participate in research or clinical trials?

Yes. Dr. Michael A. Gorin has published 356 articles and abstracts on conditions like Renal Oncocytoma. You can view a list of Dr. Michael A. Gorin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael A. Gorin accept my insurance?

Dr. Michael A. Gorin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 301-724-0132 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gorin's expertise for a condition
ConditionClose
View All 19 Advanced Conditions
View All 44 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile